Rehabilitation Robots MarketSize, Share & Industry Analysis, 2026-2034By TypeBy Robotic StructureBy ExtremityBy Mobility ModeBy ApplicationBy Patient Age GroupBy Control TechnologyBy Actuation TechnologyBy ComponentBy End UserBy Sales Channel

Rehabilitation robots are powered, sensor-guided machines that help patients regain movement lost to stroke, spinal cord injury, brain injury, neurological disease or orthopaedic trauma. They take the form of fixed therapy stations, treadmill and overground gait trainers, wearable exoskeletons, assistive arms and remote or neural-interface systems, sold with the software and services that run them. Buyers are hospitals, rehabilitation centres, specialty clinics, research institutes, sports and wellness facilities and, increasingly, patients and carers using devices at home.

The global rehabilitation robots market stood at USD 1.7 billion in 2025. A forecast-period rate of 16.51% takes it to USD 6.72 billion by 2034, and the study reports every year in between, passing USD 0.63 billion in 2020, USD 1.4 billion in 2024, USD 1.98 billion in 2026 and USD 3.648 billion in 2030.

The type mix shifts over the period. Therapy Robots is the largest line in 2025 at USD 0.646 billion, a 38% share, moving to USD 2.083 billion and 31% by 2034. Brain-Computer Interface Robots grows fastest at 26.9%, taking its share from 4% to 9%, while Assistive Robots grows slowest at 13%. Share moves toward Telerehabilitation Robots and Brain-Computer Interface Robots and away from Therapy Robots, Assistive Robots and Exoskeletons, though no line shrinks in revenue terms.

Cut by robotic structure, the largest line is Exoskeleton Robots: 45% of 2025 revenue, worth USD 0.765 billion, and 47% at USD 3.159 billion by 2034. Hybrid Robots grows faster at 18.1% against 17.1%, moving from 15% of revenue to 17% by 2034. Both this axis and the type one divide the same revenue, which is why they are alternative views, not components.

The regional order runs from North America at 38% of 2025 revenue down to Latin America at 4%. North America is worth USD 0.646 billion in 2025 and USD 2.15 billion in 2034; Europe, second at 28%, moves from USD 0.476 billion to USD 1.68 billion. Asia Pacific gain share across the period, so growth is not distributed evenly between regions.

Behind these figures sit five regions, five type lines and eleven segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is a triangulation of published figures and category proxies, short of a directly sourced total, and the same applies to the segment, regional and country breakdowns drawn from it.

• A forecast-period rate of 16.51% takes the market from USD 1.7 billion in 2025 to USD 6.72 billion in 2034, against 21.96% recorded over the 2020-2025 historical period.
• 38% of 2025 revenue sits in Therapy Robots (USD 0.646 billion) and it remains the largest type line in 2034 at USD 2.083 billion and 31%.
• Brain-Computer Interface Robots is the fastest-growing line at 26.9%, lifting its share from 4% in 2025 to 9% in 2034 and its revenue from USD 0.068 billion to USD 0.605 billion.
• Against a base case of USD 6.72 billion in 2034, the study also reports a bear case at USD 5.003 billion and a bull case at USD 8.123 billion, with the assumptions behind each set out separately.
• 38% of 2025 revenue is generated in North America, worth USD 0.646 billion and rising to USD 2.15 billion by 2034; Latin America is smallest at 4%.
• The United States accounts for 87.9% of North America in the base year, worth USD 0.568 billion in 2025 and reaching USD 1.87 billion by 2034, the worked country example carried through that region's chapters.
• Every line on all eleven segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

The global rehabilitation robots market is shaped over 2026-2034 by three measurable movements: a change in the type mix, a shift in where revenue sits geographically, and the 16.51% rate carrying the total.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; what separates them is which takes the larger part of the growth.

Brain-Computer Interface Robots outpaces Assistive Robots. 26.9% against 13%: that gap, between Brain-Computer Interface Robots and Assistive Robots, is the largest on the type axis. Brain-Computer Interface Robots takes its share of revenue from 4% to 9% while Assistive Robots gives up ground, from 17% to 13%. Revenue rises on both sides; USD 0.068 billion to USD 0.605 billion and USD 0.289 billion to USD 0.874 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

Regional weight shifts toward Asia Pacific. Asia Pacific moves from 24% of revenue in 2025 to 33% in 2034, worth USD 0.408 billion rising to USD 2.218 billion. The offsetting side is North America at 38% moving to 32%, Europe at 28% moving to 25%, Latin America at 4% moving to 4%, Middle East and Africa at 6% moving to 6%, none of which contracts. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.

Growth compounds at 16.51% without a step change. Year by year the total runs USD 0.63 billion in 2020, USD 1.4 billion in 2024, USD 1.7 billion in 2025, USD 1.98 billion in 2026, USD 3.648 billion in 2030 and USD 6.72 billion in 2034. The forecast rate of 16.51% sits against 21.96% over the historical period, so the projection extends an observed trend instead of proposing a new one. For a participant that makes planning a question of capturing a share of steady expansion instead of timing a discontinuity, and it is why the type and regional mixes matter more to a forecast than the headline rate does.

Brain-Computer Interface Robots adds the most incremental growth

Three sources account for the growth to 2034: 16.51% compounding across the base, share moving toward the faster type lines, and above-market expansion in the leading regions.

What holds the forecast back

Where the forecast could be beaten

The total depends on a single line

USD 0.646 billion of 2025 revenue is generated in North America, 38% of the global rehabilitation robots market rising to USD 2.15 billion in 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

Share settles at 32% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

Segment composition follows the global pattern: Therapy Robots largest at 38% of 2025 revenue, Brain-Computer Interface Robots fastest at 26.9%. Per-axis and per-country detail for North America sits in the full report.

The largest single market in North America is the United States, at USD 0.568 billion in 2025 and USD 1.87 billion in 2034. At 87.9% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Set against USD 0.646 billion and USD 2.15 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is Therapy Robots at 38% of 2025 revenue, easing to 31% by 2034, and the fastest is Brain-Computer Interface Robots at 26.9%, from 4% to 9%. Since 87.9% of North America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports the United States by type separately.

Rehabilitation robots are regulated by the Food and Drug Administration as medical devices under the Federal Food, Drug, and Cosmetic Act. Most powered exoskeletons and therapy robots fall into a moderate-risk class and reach the market through premarket notification, with a de novo request for novel designs and full premarket approval reserved for the highest-risk products. Suppliers must register their establishment, list the device, operate a quality system, report adverse events and meet labelling rules. Conformity to recognised consensus standards for electrical safety, software lifecycle and usability is expected as supporting evidence.

In the United States the field is DIH Holding US, Inc. (Hocoma), Ekso Bionics Holdings, Inc., ReWalk Robotics Ltd. (Lifeward), Cyberdyne Inc., Fourier Intelligence Co., Ltd., Bionik Laboratories Corp., Myomo, Inc., Hocoma AG, Toyota Motor Corporation, Honda Motor Co., Ltd., Panasonic Holdings Corporation, Parker Hannifin Corporation, Bioness Inc., Instead Technologies Ltd., Motorika Medical Ltd., Barrett Technology, LLC, Tyromotion GmbH, Reha Technology AG, Kinova Inc., Wandercraft SAS, Harmonic Bionics, Inc., Gogoa Mobility Robots S.L., Neofect Co., Ltd., AlterG, Inc., Ottobock SE & Co. KGaA, Technaid S.L., Rehab-Robotics Company Limited and Shenzhen Milebot Robotics Co., Ltd.. Therapy Robots, at 38% of 2025 revenue, is where the volume sits, and Brain-Computer Interface Robots, growing at 26.9%, is where position changes hands over the forecast period. Country-level shares and positioning per company sit in the full report.

Canada is sized at USD 0.052 billion in 2025, rising to USD 0.16 billion by 2034; 3.1% of global revenue and 8% of North America. It is reported separately from the United States across every segmentation axis in the full report.

In Europe, 28% of global revenue puts 2025 at USD 0.476 billion on the way to USD 1.68 billion by 2034. That makes it the second-largest region covered, in 2025 and again in 2034.

Share settles at 25% in 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Segment composition follows the global pattern: Therapy Robots largest at 38% of 2025 revenue, Brain-Computer Interface Robots fastest at 26.9%. Per-axis and per-country detail for Europe sits in the full report.

25.2% of Europe's base-year revenue comes from Germany; USD 0.12 billion, rising to USD 0.42 billion by 2034. At 25.2% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. The region itself runs USD 0.476 billion to USD 1.68 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Therapy Robots at 38% of 2025 revenue, easing to 31% by 2034, and the fastest is Brain-Computer Interface Robots at 26.9%, from 4% to 9%. With 25.2% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-type revenue for Germany appears on its own in the full report.

Germany applies the European Union Medical Device Regulation, enforced nationally by the Federal Institute for Drugs and Medical Devices and the state authorities. Rehabilitation robots are generally classified by risk, and most above the lowest class require assessment by a notified body before the CE mark can be affixed. Suppliers must maintain a quality management system, technical documentation, clinical evaluation and post-market surveillance, and obtain a unique device identifier. Harmonised standards for electrical safety, software, risk management and usability support the conformity claim, and labelling must be available in German.

DIH Holding US, Inc. (Hocoma), Ekso Bionics Holdings, Inc., ReWalk Robotics Ltd. (Lifeward), Cyberdyne Inc., Fourier Intelligence Co., Ltd., Bionik Laboratories Corp., Myomo, Inc., Hocoma AG, Toyota Motor Corporation, Honda Motor Co., Ltd., Panasonic Holdings Corporation, Parker Hannifin Corporation, Bioness Inc., Instead Technologies Ltd., Motorika Medical Ltd., Barrett Technology, LLC, Tyromotion GmbH, Reha Technology AG, Kinova Inc., Wandercraft SAS, Harmonic Bionics, Inc., Gogoa Mobility Robots S.L., Neofect Co., Ltd., AlterG, Inc., Ottobock SE & Co. KGaA, Technaid S.L., Rehab-Robotics Company Limited and Shenzhen Milebot Robotics Co., Ltd. are the suppliers covered in Germany. Two different problems sit on the same axis: holding Therapy Robots at 38% of 2025 revenue, and taking Brain-Computer Interface Robots while it grows at 26.9%. A supplier weighted toward Europe is competing over a base of USD 0.476 billion in 2025 reaching USD 1.68 billion by 2034, 28% of global revenue at the start of that period.

Within Europe, the United Kingdom accounts for 14.3% of regional revenue and 4% of the global total, worth USD 0.068 billion in 2025 and USD 0.23 billion by 2034.

Within Europe, France accounts for 13% of regional revenue and 3.6% of the global total, worth USD 0.062 billion in 2025 and USD 0.215 billion by 2034.

Asia Pacific holds 24% of the global rehabilitation robots market in 2025, worth USD 0.408 billion and reaches USD 2.218 billion by 2034. It is a leading region on this axis, third by revenue throughout the period.

Its share rises to 33% over the forecast period, because it outgrows the market's 16.51%; the revenue added here is disproportionate to where the region started.

Segment composition follows the global pattern: Therapy Robots largest at 38% of 2025 revenue, Brain-Computer Interface Robots fastest at 26.9%. The full report breaks Asia Pacific out along every axis and by country.

36.8% of Asia Pacific's base-year revenue comes from China; USD 0.15 billion, rising to USD 0.9 billion by 2034. 36.8% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 0.408 billion in 2025 and USD 2.218 billion in 2034, it is the country the full report breaks out in detail.

Demand in China follows the type mix reported at global level: Therapy Robots is the largest line at 38% of 2025 revenue, moving to 31% by 2034, while Brain-Computer Interface Robots grows fastest at 26.9% and takes its share from 4% to 9%. Since 36.8% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. China carries its own type breakdown in the full report.

The National Medical Products Administration regulates rehabilitation robots under the Regulations on the Supervision and Administration of Medical Devices. Products are sorted into classes by risk, and powered robotic systems usually sit in the higher classes that require registration with a type test at an approved testing institute, clinical evaluation and a quality system inspection. Imported products need a local legal agent holding the registration. Mandatory national and industry standards for electrical safety and electromagnetic compatibility apply, and labels and instructions must be in Chinese.

The suppliers tracked in this study (DIH Holding US, Inc. (Hocoma), Ekso Bionics Holdings, Inc., ReWalk Robotics Ltd. (Lifeward), Cyberdyne Inc., Fourier Intelligence Co., Ltd., Bionik Laboratories Corp., Myomo, Inc., Hocoma AG, Toyota Motor Corporation, Honda Motor Co., Ltd., Panasonic Holdings Corporation, Parker Hannifin Corporation, Bioness Inc., Instead Technologies Ltd., Motorika Medical Ltd., Barrett Technology, LLC, Tyromotion GmbH, Reha Technology AG, Kinova Inc., Wandercraft SAS, Harmonic Bionics, Inc., Gogoa Mobility Robots S.L., Neofect Co., Ltd., AlterG, Inc., Ottobock SE & Co. KGaA, Technaid S.L., Rehab-Robotics Company Limited and Shenzhen Milebot Robotics Co., Ltd.) compete in China across the type lines above. The commercially relevant division is 38% of 2025 revenue in Therapy Robots, where the volume is, against 26.9% growth in Brain-Computer Interface Robots, where share moves. A supplier weighted toward Asia Pacific is competing over a base of USD 0.408 billion in 2025 reaching USD 2.218 billion by 2034, 24% of global revenue at the start of that period.

Japan is sized at USD 0.11 billion in 2025, rising to USD 0.42 billion by 2034; 6.5% of global revenue and 27% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

Within Asia Pacific, South Korea accounts for 9.8% of regional revenue and 2.4% of the global total, worth USD 0.04 billion in 2025 and USD 0.17 billion by 2034.

Latin America holds 4% of the global rehabilitation robots market in 2025, worth USD 0.068 billion and reaches USD 0.269 billion by 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

Its share moves to 4% by 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Therapy Robots leads here as it does globally, at 38% of 2025 revenue, and Brain-Computer Interface Robots again grows fastest at 26.9%. Latin America is reported axis by axis and country by country in the full study.

47.1% of Latin America's base-year revenue comes from Brazil; USD 0.032 billion, rising to USD 0.125 billion by 2034. 47.1% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 0.068 billion in 2025 and USD 0.269 billion in 2034, it is the country the full report breaks out in detail.

The type pattern in Brazil is the global one: 38% of 2025 revenue in Therapy Robots, 31% by 2034, against 26.9% growth in Brain-Computer Interface Robots taking it from 4% to 9%. With 47.1% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports Brazil by type separately.

The National Health Surveillance Agency, known as ANVISA, governs rehabilitation robots as medical devices. Products are classified by risk, and robotic systems generally fall into the higher classes that require registration rather than simple notification. Foreign manufacturers must appoint a Brazilian registration holder and demonstrate compliance with Good Manufacturing Practice, normally through an agency inspection or an accepted audit programme. Electrical medical equipment must obtain certification of conformity from an accredited body under the national compulsory certification scheme, which relies on the international standards for basic safety of medical electrical equipment as adopted locally. Labelling and instructions must be in Portuguese.

In Brazil the field is DIH Holding US, Inc. (Hocoma), Ekso Bionics Holdings, Inc., ReWalk Robotics Ltd. (Lifeward), Cyberdyne Inc., Fourier Intelligence Co., Ltd., Bionik Laboratories Corp., Myomo, Inc., Hocoma AG, Toyota Motor Corporation, Honda Motor Co., Ltd., Panasonic Holdings Corporation, Parker Hannifin Corporation, Bioness Inc., Instead Technologies Ltd., Motorika Medical Ltd., Barrett Technology, LLC, Tyromotion GmbH, Reha Technology AG, Kinova Inc., Wandercraft SAS, Harmonic Bionics, Inc., Gogoa Mobility Robots S.L., Neofect Co., Ltd., AlterG, Inc., Ottobock SE & Co. KGaA, Technaid S.L., Rehab-Robotics Company Limited and Shenzhen Milebot Robotics Co., Ltd.. Therapy Robots, at 38% of 2025 revenue, is where the volume sits, and Brain-Computer Interface Robots, growing at 26.9%, is where position changes hands over the forecast period. The commercial size of that position is USD 0.068 billion in 2025, moving to USD 0.269 billion by 2034 across the forecast period.

Within Latin America, Mexico accounts for 23.5% of regional revenue and 0.9% of the global total, worth USD 0.016 billion in 2025 and USD 0.068 billion by 2034.

In Middle East and Africa, 6% of global revenue puts 2025 at USD 0.102 billion rising to USD 0.403 billion in 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.

Share settles at 6% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

Therapy Robots leads here as it does globally, at 38% of 2025 revenue, and Brain-Computer Interface Robots again grows fastest at 26.9%. The full report breaks Middle East and Africa out along every axis and by country.

The largest single market in Middle East and Africa is Saudi Arabia, at USD 0.026 billion in 2025 and USD 0.11 billion in 2034. Its 25.5% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. Regional revenue of USD 0.102 billion in 2025 and USD 0.403 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in Saudi Arabia follows the type mix reported at global level: Therapy Robots is the largest line at 38% of 2025 revenue, moving to 31% by 2034, while Brain-Computer Interface Robots grows fastest at 26.9% and takes its share from 4% to 9%. Because the country carries 25.5% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-type revenue for Saudi Arabia appears on its own in the full report.

The Saudi Food and Drug Authority regulates medical devices, including rehabilitation robots, under its medical devices interim regulation. Devices are classified by risk, and manufacturers must have an authorised representative in the Kingdom, which then obtains marketing authorisation for the product. Suppliers must hold a medical device establishment licence or work with a licensed importer, and show evidence of a quality management system and conformity with recognised international standards. Approval in a reference jurisdiction can support the file. Labelling must include Arabic information, and post-market vigilance reporting is required.

DIH Holding US, Inc. (Hocoma), Ekso Bionics Holdings, Inc., ReWalk Robotics Ltd. (Lifeward), Cyberdyne Inc., Fourier Intelligence Co., Ltd., Bionik Laboratories Corp., Myomo, Inc., Hocoma AG, Toyota Motor Corporation, Honda Motor Co., Ltd., Panasonic Holdings Corporation, Parker Hannifin Corporation, Bioness Inc., Instead Technologies Ltd., Motorika Medical Ltd., Barrett Technology, LLC, Tyromotion GmbH, Reha Technology AG, Kinova Inc., Wandercraft SAS, Harmonic Bionics, Inc., Gogoa Mobility Robots S.L., Neofect Co., Ltd., AlterG, Inc., Ottobock SE & Co. KGaA, Technaid S.L., Rehab-Robotics Company Limited and Shenzhen Milebot Robotics Co., Ltd. are the suppliers covered in Saudi Arabia. Volume sits in Therapy Robots at 38% of 2025 revenue; movement sits in Brain-Computer Interface Robots at 26.9% growth. A supplier weighted toward Middle East and Africa is competing over a base of USD 0.102 billion in 2025 reaching USD 0.403 billion by 2034, 6% of global revenue at the start of that period.

The United Arab Emirates is sized at USD 0.02 billion in 2025, rising to USD 0.085 billion by 2034; 1.2% of global revenue and 19.6% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.

0.8% of global revenue is generated in South Africa; USD 0.014 billion in 2025, reaching USD 0.045 billion in 2034, and 13.7% of Middle East and Africa.

Download a free sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, robotic structure, extremity, mobility mode, application, patient age group, control technology, actuation technology, component, end user, sales channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.